cloxacillin
Trade name: pathocil
Small moleculeapproved
Approved
May 9, 1968
Cloxacillin is a derivative of penicillin for the treatment of broad spectrum of bacterial infections. The drug exerts its action by inhiiting bacterial beta-lactamase (penicillin-binding proteins). — NCATS
Clinical trial activity
19 trials · 25 clinical orgs · 4 marketing orgs
Phase 1
0
Phase 2
7
Phase 3
5
Phase 4
5
Earliest trial started Apr 1, 2002 (NCT00129688)
Timeline
1960s
- May 9, 1968
American Home Products — Earliest FDA Approval
- May 9, 1968
American Home Products — NDA Organization
1970s
- Apr 1, 1971
Apothecon — Marketing Organization
- Sep 17, 1974
GlaxoSmithKline — Marketing Organization
1980s
- Jun 5, 1980
Teva — Marketing Organization
2000s
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
2010s
- Jan 1, 2013
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
- Arthritis, Infectious (approved 1982)
- Endocarditis, Bacterial (approved 1982)
- Meningitis, Bacterial (approved 1982)
- Osteomyelitis (approved 1982)
- Otitis Media (approved 1982)
- Respiratory Tract Infections (approved 1982)
- Sepsis (approved 1982)
- Skin Diseases, Infectious (approved 1982)
- Urinary Tract Infections (approved 1982)
Studied for
- Abscess · Phase 4
- Arthritis, Infectious · Phase 4
- Central Nervous System Infections · Phase 4
- Dermatology · Phase 4
- Diabetes Mellitus · Phase 4
- Endocarditis · Phase 3
- Gram-Positive Bacterial Infections · Phase 2
- Hematologic Neoplasms · Phase 2
- Invasive Fungal Infections · Phase 4
- Kidney Failure, Chronic · Phase 4
- Lymphopenia · Phase 2
- Osteomyelitis · Phase 4
- Staphylococcal Infections · Phase 4
- Staphylococcus · Phase 3
- Staphylococcus aureus · Phase 4
Mechanism of action
- Penicillin-binding proteinINHIBITOR
Penicillin-binding protein inhibitor
Indicated for staphylococcal infections
- Penicillin-binding protein 4 (pbp4) ↗
- Cell division protein FtsI [Peptidoglycan synthetase] / Transpeptidase, Penicillin binding protein transpeptidase domain, Penicillin-binding protein 3 (pbpF) ↗
- MecA PBP2' (penicillin binding protein 2') (Q53707) ↗
- Penicillin-binding protein 2 (Q53729) ↗
- Cell division protein FtsI (Peptidoglycan synthetase) (pbpA) ↗
Approval history
- approvedMay 9, 1968
Chemistry & pharmacology
Loading structure…
SMILES
Cc1onc(-c2ccccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O- Mol. weight
- 435.89 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL891 ↗
- WikipediaCloxacillin ↗
- NCATSO6X5QGC2VB ↗
- ChEMBLCHEMBL1200388 ↗
Also known as
- (2s,5r,6r)-6-({[3-(2-chlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
- (2s,5r,6r)-6-({[3-(2-chlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
- (3-(o-chlorophenyl)-5-methyl-4-isoxazolyl)penicillin
- (3-(o-chlorophenyl)-5-methyl-4-isoxazolyl)penicillin
- 6-(3-(o-chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid
- 6-(3-(o-chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid
- brl-1621
- brl-1621
- cloxacilina
- cloxacilina
- cloxacillin
- cloxacillin
- cloxacillin
- cloxacillin
- cloxacillin
- cloxacillin
- cloxacillin
- cloxacillin
- cloxacillin
- cloxacillin
- cloxacillin
- cloxacilline
- cloxacilline
- cloxacillin sodium
- cloxacillin sodium
- cloxacillin sodium
- cloxacillin sodium
- cloxacillin sodium salt
- cloxacillinum
- cloxacillinum
- cloxapen
- cloxapen
- dariclox
- ekvacillin
- ekvacillin
- methocillin s
- orbenin
- orbenin
- p-25
- p-25
- tegopen
- tegopen
- tegopen
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06756191 | Phase 4 | Jan 10, 2025 | Capital Medical University |
| NCT06726395 | Phase 4 | Dec 31, 2024 | Lund University, Region Skane |
| NCT06719661 | N/A | Dec 1, 2024 | University of Sulaimani |
| NCT06584006 | Phase 2 | Sep 1, 2024 | Xiamen University |
| NCT06336824 | Phase 3 | Jun 28, 2024 | Clinical Research Centre, Malaysia, Government of Malaysia |
| NCT06470425 | N/A | Feb 2, 2024 | Solvay, Triangel Scientific |
| NCT06470399 | N/A | Feb 2, 2023 | Solvay |
| NCT04141787 | Phase 4 | Jul 11, 2019 | Vancouver Island Health Authority |
| NCT03959345 | Phase 4 | May 21, 2019 | Universidad Carlos III Madrid, University of Barcelona |
| NCT03248063 | N/A | Sep 5, 2018 | Assistance Publique - Hôpitaux de Paris |
| NCT03246360 | N/A | Aug 31, 2017 | University of Nice Sophia Antipolis |
| NCT02701608 | Phase 3 | Mar 1, 2016 | François Rabelais University, University of Toulouse |
| NCT02701595 | Phase 3 | Mar 1, 2016 | François Rabelais University, University of Toulouse |
| NCT01792804 | Phase 3 | Dec 1, 2013 | German Research Foundation, University of Duesseldorf |
| NCT01875263 | Phase 3 | May 1, 2013 | Government of Spain |
| NCT01104662 | Phase 4 | Apr 1, 2010 | Cubist |
| NCT00885300 | N/A | Jan 1, 2008 | University of Tehran |
| NCT00062647 | Phase 2 | Aug 1, 2003 | Duke University, Theravance |
| NCT00129688 | N/A | Apr 1, 2002 | KhonKaen University, National Research Council of Thailand |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (25)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| François Rabelais University | Academic/Hospital | 2 | 0 | 1 | 2016 |
| Solvay | For profit | 2 | 2 | 1 | 2023 |
| University of Toulouse | Academic/Hospital | 2 | 2 | 1 | 2016 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Clinical Research Centre, Malaysia | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Cubist | For profit | 1 | 1 | 1 | 2010 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2003 |
| German Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Government of Malaysia | Government | 1 | 0 | 1 | 2024 |
| Government of Spain | Government | 1 | 1 | 1 | 2013 |
| KhonKaen University | Academic/Hospital | 1 | 1 | 1 | 2002 |
| Lund University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| National Research Council of Thailand | Government | 1 | 0 | 1 | 2002 |
| Region Skane | Government | 1 | 1 | 1 | 2024 |
| Theravance | For profit | 1 | 1 | 1 | 2003 |
| Triangel Scientific | For profit | 1 | 0 | 1 | 2024 |
| Universidad Carlos III Madrid | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Barcelona | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Duesseldorf | Academic/Hospital | 1 | 1 | 1 | 2013 |
25 organizations
Page 1 / 2
Marketing (5)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| American Home Products | For profit | NDA | May 9, 1968 |
| Apothecon | For profit | MKTG | Apr 1, 1971 |
| Apothecon | For profit | NDA2 | — |
| GlaxoSmithKline | For profit | MKTG | Sep 17, 1974 |
| Teva | For profit | MKTG | Jun 5, 1980 |